BACKGROUND: The Framingham risk estimation (FRE) serves as the basis for identifying which asymptomatic adults should be treated with aspirin and lipid-lowering therapy in primary prevention. However, the FRE generally yields low estimates of 10-year "hard" coronary heart disease (CHD) event risk with few women (< 70 years) qualifying for preventive pharmacologic therapy despite relatively high lifetime risk. We postulated that traditional risk factor assessment might fail to identify a sizeable portion of women with a sibling history for premature CHD as having advanced subclinical atherosclerosis. METHODS: We studied 102 asymptomatic women (mean age 51 +/- 7 years) who were the sisters of a proband hospitalized with documented premature CHD. Participants underwent risk factor assessment and multidetector computed tomography for coronary artery calcium (CAC) scoring. Based on FRE prediction of 10-year risk for hard CHD events, participants were classified as low risk (< 10%) (n = 100), intermediate risk (10%-20%) (n = 2), or high risk (> 20%) (n = 0). Significant subclinical atherosclerosis was defined as age-sex adjusted > 75th percentile CAC scores. RESULTS: Ninety-eight percent were at low risk (mean FRE of only 2% +/- 2%). However, 40% had detectable CAC, 12% had CAC > 100, and 6% had CAC > or = 400. Based on CAC score percentiles, 32% had significant subclinical atherosclerosis and 17% ranked above the 90th percentile. CONCLUSION: Among women classified as low risk by FRE, a third had significant subclinical atherosclerosis. Sisters of probands with premature CHD appear to be a high-risk group and may warrant noninvasive screening for subclinical atherosclerosis to appropriately target individuals for more aggressive primary prevention therapy than what is currently recommended.
BACKGROUND: The Framingham risk estimation (FRE) serves as the basis for identifying which asymptomatic adults should be treated with aspirin and lipid-lowering therapy in primary prevention. However, the FRE generally yields low estimates of 10-year "hard" coronary heart disease (CHD) event risk with few women (< 70 years) qualifying for preventive pharmacologic therapy despite relatively high lifetime risk. We postulated that traditional risk factor assessment might fail to identify a sizeable portion of women with a sibling history for premature CHD as having advanced subclinical atherosclerosis. METHODS: We studied 102 asymptomatic women (mean age 51 +/- 7 years) who were the sisters of a proband hospitalized with documented premature CHD. Participants underwent risk factor assessment and multidetector computed tomography for coronary artery calcium (CAC) scoring. Based on FRE prediction of 10-year risk for hard CHD events, participants were classified as low risk (< 10%) (n = 100), intermediate risk (10%-20%) (n = 2), or high risk (> 20%) (n = 0). Significant subclinical atherosclerosis was defined as age-sex adjusted > 75th percentile CAC scores. RESULTS: Ninety-eight percent were at low risk (mean FRE of only 2% +/- 2%). However, 40% had detectable CAC, 12% had CAC > 100, and 6% had CAC > or = 400. Based on CAC score percentiles, 32% had significant subclinical atherosclerosis and 17% ranked above the 90th percentile. CONCLUSION: Among women classified as low risk by FRE, a third had significant subclinical atherosclerosis. Sisters of probands with premature CHD appear to be a high-risk group and may warrant noninvasive screening for subclinical atherosclerosis to appropriately target individuals for more aggressive primary prevention therapy than what is currently recommended.
Authors: Randy Cohen; Matthew Budoff; Robyn L McClelland; Stefan Sillau; Gregory Burke; Michael Blaha; Moyses Szklo; Seth Uretsky; Alan Rozanski; Steven Shea Journal: Am J Cardiol Date: 2014-07-30 Impact factor: 2.778
Authors: Leslee J Shaw; Daniel S Berman; Roger S Blumenthal; Matthew J Budoff; Tracy L Faber; Tauqir Goraya; Sandra S Halliburton; Harvey Hecht; Hosen Kiat; Wolfgang Koenig; Shaista Malik; Michael Merhige; Khurram Nasir; James K Min; James O'Keefe; Donna M Polk; Paolo Raggi; Jeffrey A Rosenblatt; Ronald G Schwartz; Allen J Taylor; Gregory S Thomas; William Wijns Journal: J Nucl Cardiol Date: 2008 Jan-Feb Impact factor: 5.952
Authors: Michael G Silverman; Michael J Blaha; Harlan M Krumholz; Matthew J Budoff; Ron Blankstein; Christopher T Sibley; Arthur Agatston; Roger S Blumenthal; Khurram Nasir Journal: Eur Heart J Date: 2013-12-23 Impact factor: 29.983
Authors: Jacques Genest; Ruth McPherson; Jiri Frohlich; Todd Anderson; Norm Campbell; André Carpentier; Patrick Couture; Robert Dufour; George Fodor; Gordon A Francis; Steven Grover; Milan Gupta; Robert A Hegele; David C Lau; Lawrence Leiter; Gary F Lewis; Eva Lonn; G B John Mancini; Dominic Ng; Glen J Pearson; Allan Sniderman; James A Stone; Ehud Ur Journal: Can J Cardiol Date: 2009-10 Impact factor: 5.223
Authors: Jesse A Lieberman; Flora M Hammond; Thomas A Barringer; H J Norton; David C Goff; William L Bockenek; William M Scelza Journal: J Spinal Cord Med Date: 2011 Impact factor: 1.985
Authors: Susan T Laing; Beverly Smulevitz; Kristina P Vatcheva; Anne R Rentfro; David D McPherson; Susan P Fisher-Hoch; Joseph B McCormick Journal: Echocardiography Date: 2012-07-02 Impact factor: 1.724